Hyperfractionated Dual Equivalent Fractionated Radiation Therapy

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Yale University
Study ID
NCT06898905
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bridging Radiation Therapy — OTHER
    Study seeks to compare the hypofractionated radiation therapy with hyperfractionated treatment within the same tumor. Each participant will be serving as their own control; half their tumor will receive once daily hypofractionated (QD) bridging radiotherapy, and the other half of their tumor will receive twice daily hyperfractionated (BID) bridging radiotherapy. Either schedule is considered standard of care and this study aims to determine which schedule may prove superior between the two standards.

Study Details

This study evaluates the feasibility and safety of a novel method for comparing the effectiveness of hypofractionated versus hyperfractionated radiation therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) undergoing T-cell redirection therapies (CAR T-cell therapy or bispecific antibodies).

Key Dates

Start date
Oct 30, 2025
Status verified
Nov 2025
Primary completion
Apr 30, 2027
Completion
Apr 30, 2027

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Dual Hyperfractionated Radiation Therapy
    All patients enrolled will receive radiation as a bridge to subsequent planned T Cell Directed therapy. The same tumor will be treated daily, with one area receiving once daily and the other receiving twice daily radiation therapy.

Primary Outcome Measure

Feasibility Assessment of Dual Fractionated Radiation Therapy Enrollment and Treatment [ Time Frame: Approximately one year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Yale UniversityNew HavenConnecticut06510
Patricia Brand
[email protected]
203-785-4095
Timothy Robinson, MD PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in New Haven, CT

By research site
Yale University· New Haven, CT

Related Studies